NetworkNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) Announces Nomination of Novel Candidate for Advancement into COVID-19 Clinical Trials
NanoViricides (NYSE American: NNVC), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, has nominated a clinical drug candidate for the treatment of COVID-19. The announcement advances the company’s COVID-19 program one step closer to human clinical trials. The company is working to accelerate its drug-development program for COVID-19 treatment. NNVC’s ultimate goal is to develop the most effective medicine and to obtain regulatory approval for emergency use in the COVID-19 pandemic in the shortest timeline feasible. With that in mind, the company is aggressively working to harness the full power of…







